Lenalidomide as a novel treatment of acute myeloid leukemia

Bibliography

• Jemal A, Siegel R, Xu J, Cancer statistics. 2010. CA Cancer J Clin 2010;60(5):277–300
   PubMed Web of Science ®Google Scholar
• Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011;29(5):487-94
   PubMed Web of Science ®Google Scholar
• Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011;117(8):2307-18
   PubMed Web of Science ®Google Scholar
• Koreth J, Schlenk R, Kopecky KJ, Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009;301(22):2349-61
   PubMed Web of Science ®Google Scholar
• Basara N, Schulze A, Wedding U, Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 2009;23(4):635-40
   PubMed Web of Science ®Google Scholar
• Gupta V, Tallman MS, He W, Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010;116(11):1839-48
   PubMed Web of Science ®Google Scholar
• Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25(14):1908-15
   PubMed Web of Science ®Google Scholar
• Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 2002;52(6):363-71
   PubMed Web of Science ®Google Scholar
• Menzin J, Lang K, Earle CC, The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002;162(14):1597-603
   PubMed Web of Science ®Google Scholar
• Oran B, Weisdorf DG. Survival for older patients with aml: a population based study. Haematologica 2012;97(12):1916-24
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, Age and acute myeloid leukemia. Blood 2006;107(9):3481-5
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Burnett AK, Wheatley K, Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the united kingdom medical research council aml11 trial. Blood 2001;98(5):1302-11
   PubMed Web of Science ®Google Scholar
• Stone RM, Berg DT, George SL, Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and leukemia group b. N Engl J Med 1995;332(25):1671-7
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the eastern cooperative oncology group. Blood 2004;103(2):479-85
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355(14):1456-65
   PubMed Web of Science ®Google Scholar
• Raza A, Reeves JA, Feldman EJ, Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111(1):86-93
   PubMed Web of Science ®Google Scholar
• Mesa RA, Tefferi A, Li CY, Steensma DP. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK 2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia 2006;20(11):2063-4
   PubMed Web of Science ®Google Scholar
• Ford CD, Asch J, Konopa K, Petersen FB. CR with lenalidomide in del(5)(q13q33) aml relapsing after allogeneic hematopoietic SCT. Bone Marrow Transplant 2010;45(2):403-4
   PubMedGoogle Scholar
• Lancet JE, List AF, Moscinski LC. Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia 2007;21(3):586-8
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Byrd JC, Marcucci G, Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 2009;113(5):1002-5
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Sekeres MA, Makishima H, Cytogenetic predictors of response to lenalidomide in myeloid malignancies without del(5q) [abstract]. Blood 2010;116(21):1637
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Sekeres MA, Makishima H, Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. J Hematol Oncol 2012;5:4
   PubMed Web of Science ®Google Scholar
• de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010;10(11):775-83
   PubMed Web of Science ®Google Scholar
• Faderl S, Gandhi V, O'Brien S, Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105(3):940-7
   PubMed Web of Science ®Google Scholar
• Faderl S, Verstovsek S, Cortes J, Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006;108(1):45-51
   PubMed Web of Science ®Google Scholar
• Faderl S, Ravandi F, Huang X, A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112(5):1638-45
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes JE, Jones D, Phase 1/2 study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28(11):1856-62
   PubMed Web of Science ®Google Scholar
• Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase 2 study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010;28(4):556-61
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28(4):562-9
   PubMed Web of Science ®Google Scholar
• Chen N, Wen L, Lau H, Pharmacokinetics, metabolism and excretion of [(14)c]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol 2012;69(3):789-97
   PubMed Web of Science ®Google Scholar
• Blum W, Klisovic RB, Becker H, Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010;28(33):4919-25
   PubMed Web of Science ®Google Scholar
• Chen N, Lau H, Kong L, Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007;47(12):1466-75
   PubMed Web of Science ®Google Scholar
• Crane E, List A. Immunomodulatory drugs. Cancer Invest 2005;23(7):625-34
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163(1):380-6
   PubMed Web of Science ®Google Scholar
• Fujita J, Mestre JR, Zeldis JB, Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001;7(11):3349-55
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Kohrt HE, Gallegos L, Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 2012;26(5):893-901
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral LG, Wong K, Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007;67(2):746-55
   PubMed Web of Science ®Google Scholar
• Dredge K, Horsfall R, Robinson SP, Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Ak phosphorylation in vitro. Microvasc Res 2005;69(1-2):56-63
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140(1):36-45
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott JB, Macdonald CD, Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002;87(10):1166-72
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98(1):210-16
   PubMed Web of Science ®Google Scholar
• Ebert BL, Pretz J, Bosco J, Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451(7176):335-9
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Jadersten M, Forsblom AM, Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007;104(27):11406-11
   PubMed Web of Science ®Google Scholar
• Wei S, Chen X, Rocha K, A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009;106(31):12974-9
   PubMed Web of Science ®Google Scholar
• Wei S, Chen X, McGraw K, Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Ades L, Boehrer S, Prebet T, Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2009;113(17):3947-52
   PubMed Web of Science ®Google Scholar
• Mollgard L, Saft L, Treppendahl MB, Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica 2011;96(7):963-71
   PubMed Web of Science ®Google Scholar
• Chen Y, Kantarjian H, Estrov Z, A phase 2 study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk 2012;12(5):341-4
   PubMed Web of Science ®Google Scholar
• Litzow MR, Othus M, Cripe LD, Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the eastern cooperative oncology group. Br J Haematol 2010;148(2):217-25
   PubMed Web of Science ®Google Scholar
• Giles F, Vey N, DeAngelo D, Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood 2009;114(19):4027-33
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Uy GL, Trinkaus K, A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011;117(6):1828-33
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Gundacker H, Lancet J, A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: southwest Oncology Group Study S0605. Blood 2011;118(3):523-8
   PubMed Web of Science ®Google Scholar
• Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69(18):7347-56
   PubMed Web of Science ®Google Scholar
• Sudan N, Rossetti JM, Shadduck RK, Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006;107(8):1839-43
   PubMed Web of Science ®Google Scholar
• Krug U, Rollig C, Koschmieder A, Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010;376(9757):2000-8
   PubMed Web of Science ®Google Scholar
• Ramsingh G, Westervelt P, Cashen AF, A phase 1 study of concomitant high dose lenalidomide and 5-azacitidine induction in the treatment of AML. Leukemia 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar